Cas:2155-94-4 3-Methyl-2-buten-1-amine manufacturer & supplier

Chemical Name:3-Methyl-2-buten-1-amine

CAS.NO:2155-94-4

Synonyms:N-Allyl-dimethylamin;1-Dimethylamino-2-propene;1-Amino-3-methyl-2-butene;N,N-methyl-allyl amine;3-dimethylaminoprop-1-ene;MFCD00038234;2-Buten-1-amine, 3-methyl-;Allylamine,N,N-dimethyl;ALLYLDIMETHYLAMINE;3-Methyl-2-buten-1-amine;N,N-dimethyl-2-propen-1-amine;N-ALLYLDIMETHYLAMINE;EINECS 218-458-7;3-methylbut-2-en-1-amine;N-ALLYDIMETHYLAMINE;Dimethylallylamine;N-ALLYL-N,N-DIMETHYLAMINE;N,N-DIMETHYLALLYAMINE;3-Dimethylamino-1-propene,N-Allyl-dimethylamin,DMAA

Molecular Formula:C₅H₁₁N

Molecular Weight:85.147

HS Code:29211980

Physical and Chemical Properties:

Melting point:0ºC

Boiling point:114.1±9.0 °C at 760 mmHg

Density:0.8±0.1 g/cm3

Index of Refraction:1.443

PSA:3.24000

Exact Mass:85.089149

LogP:1.10

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2733 3/PG 2

Packing Group:I; II; III

Contact us for information like N-Allyl-dimethylamin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Dimethylamino-1-propene,N-Allyl-dimethylamin,DMAA physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00038234 Use and application,3-Methyl-2-buten-1-amine technical grade,usp/ep/jp grade.

Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 3-Methyl-2-buten-1-amine manufacturer Schimpke, an assistant professor in the Division of Minimally Invasive and Bariatric Surgery at Rush Medical College in Chicago, and his colleagues point out that obesity is linked to a considerably higher risk for developing upwards of 40 different serious illnesses, including heart disease and diabetes. 3-Methyl-2-buten-1-amine supplier Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. 3-Methyl-2-buten-1-amine vendor Schimpke, an assistant professor in the Division of Minimally Invasive and Bariatric Surgery at Rush Medical College in Chicago, and his colleagues point out that obesity is linked to a considerably higher risk for developing upwards of 40 different serious illnesses, including heart disease and diabetes. 3-Methyl-2-buten-1-amine factory In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.